I do not agree. Sophs were pushing shareprice 2 months ago to...

I do not agree.

Sophs were pushing shareprice 2 months ago to 1.7 to offload their options.
Once that was achieved the shareprice started to sink inevitably to current levels.

This is the broker's game.
I do not see this entirely PNO's game though.
JP played along for his own benefit and to let PNO survive.
He is the CR specialist.
In case of real revenue coming PNO's way, management will restructure.



OBJ has just advertised to fill positions of New Product Development Managers in the UK and in AUS.
Those salaries will amount to nearly half a mil per year and it is clearly obvious that OBJ expects license deal and royalty income streams to be able to hire like this.

We also have a clear indication that the UK advertisement alludes to partners in the UK, which shows that this development was initiated by partners or is an extension of a partner project.


When we further assume that OBJ does indeed uses Tripeptofen as active ingredient of their pain patch, then we are much closer to great news than expected.
A Tripeptofen pain patch development with UK exposure through 3M manufacturing experties ( remember that 3M had an MTA for 8 months with OBJ last year ) would send the shareprice of PNO to much higher levels.

Apart from that, be sure that CPS wants the options in the money and cash in twice, it's what they do well.
I doubt they stay around for fundamental developments of the company, they might just make their quick buck and move on.